Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1070

1.

Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy.

Meregalli C, Fumagalli G, Alberti P, Canta A, Carozzi VA, Chiorazzi A, Monza L, Pozzi E, Sandelius Å, Blennow K, Zetterberg H, Marmiroli P, Cavaletti G.

Exp Neurol. 2018 Jun 13. pii: S0014-4886(18)30189-4. doi: 10.1016/j.expneurol.2018.06.005. [Epub ahead of print]

PMID:
29908147
2.

Update on biomarkers for amyloid pathology in Alzheimer's disease.

Ashton NJ, Schöll M, Heurling K, Gkanatsiou E, Portelius E, Höglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H.

Biomark Med. 2018 Jun 15. doi: 10.2217/bmm-2017-0433. [Epub ahead of print]

PMID:
29902934
3.

S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.

Leinonen V, Rauramaa T, Johansson J, Bottelbergs A, Tesseur I, van der Ark P, Pemberton D, Koivisto AM, Jääskeläinen JE, Hiltunen M, Herukka SK, Blennow K, Zetterberg H, Jokinen P, Rokka J, Helin S, Haaparanta-Solin M, Solin O, Okamura N, Kolb HC, Rinne JO.

J Alzheimers Dis. 2018;64(1):171-179. doi: 10.3233/JAD-180071.

PMID:
29865068
4.

Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals Aβ Aggregation Dependent Anionic Lipid Accumulations and Metabolism.

Michno W, Kaya I, Nyström S, Guerard L, Nilsson KPR, Hammarström P, Blennow K, Zetterberg H, Hanrieder J.

Anal Chem. 2018 Jun 19. doi: 10.1021/acs.analchem.8b01361. [Epub ahead of print]

PMID:
29856605
5.

Validity and Normative Data for the Biber Figure Learning Test: A Visual Supraspan Memory Measure.

Gifford KA, Liu D, Neal JE, Acosta LMY, Bell SP, Wiggins ME, Wisniewski KM, Godfrey M, Logan LA, Hohman TJ, Pechman KR, Libon DJ, Blennow K, Zetterberg H, Jefferson AL.

Assessment. 2018 May 1:1073191118773870. doi: 10.1177/1073191118773870. [Epub ahead of print]

PMID:
29809069
6.

Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review.

Knorr U, Simonsen AH, Zetterberg H, Blennow K, Hasselbalch SG, Kessing LV.

Eur Neuropsychopharmacol. 2018 May 22. pii: S0924-977X(18)30110-X. doi: 10.1016/j.euroneuro.2018.04.002. [Epub ahead of print] Review.

PMID:
29802040
7.

Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.

Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Bennett DA, Schneider JA, Jefferson AL; Alzheimer’s Disease Genetics Consortium and the Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2018 May 7. doi: 10.1001/jamaneurol.2018.0821. [Epub ahead of print]

PMID:
29801024
8.

A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older.

Arnoldussen IAC, Sundh V, Bäckman K, Kern S, Östling S, Blennow K, Zetterberg H, Skoog I, Kiliaan AJ, Gustafson DR.

J Alzheimers Dis. 2018;63(4):1325-1335. doi: 10.3233/JAD-180099.

PMID:
29758945
9.

From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease.

Zetterberg H, Blennow K.

J Alzheimers Dis. 2018;64(s1):S271-S279. doi: 10.3233/JAD-179926.

PMID:
29758941
10.

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.

Thordardottir S, Rodriguez-Vieitez E, Almkvist O, Ferreira D, Saint-Aubert L, Kinhult-Ståhlbom A, Thonberg H, Schöll M, Westman E, Wall A, Eriksdotter M, Zetterberg H, Blennow K, Nordberg A, Graff C.

Alzheimers Res Ther. 2018 May 10;10(1):45. doi: 10.1186/s13195-018-0374-y.

11.

Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study.

Bergman L, Zetterberg H, Kaihola H, Hagberg H, Blennow K, Åkerud H.

PLoS One. 2018 May 2;13(5):e0196025. doi: 10.1371/journal.pone.0196025. eCollection 2018.

12.

Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities.

Osborn KE, Liu D, Samuels LR, Moore EE, Cambronero FE, Acosta LMY, Bell SP, Babicz MA, Gordon EA, Pechman KR, Davis LT, Gifford KA, Hohman TJ, Blennow K, Zetterberg H, Jefferson AL.

Neurobiol Aging. 2018 Aug;68:18-25. doi: 10.1016/j.neurobiolaging.2018.03.028. Epub 2018 Apr 3.

PMID:
29702372
13.

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.

Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, Zetterberg H, Sandelius Å, Shaw LM, Lee VMY, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk DA, McCluskey L, Elman L, McBride J, Toledo JB, Trojanowski JQ, Blennow K.

Acta Neuropathol. 2018 Apr 26. doi: 10.1007/s00401-018-1851-x. [Epub ahead of print]

PMID:
29700597
14.

Cerebrospinal fluid markers of extracellular matrix remodelling, synaptic plasticity and neuroinflammation before and after cranial radiotherapy.

Fernström E, Minta K, Andreasson U, Sandelius Å, Wasling P, Brinkmalm A, Höglund K, Blennow K, Nyman J, Zetterberg H, Kalm M.

J Intern Med. 2018 Apr 17. doi: 10.1111/joim.12763. [Epub ahead of print]

PMID:
29664192
15.

Neurofilament light and tau as blood biomarkers for sports-related concussion.

Shahim P, Tegner Y, Marklund N, Blennow K, Zetterberg H.

Neurology. 2018 May 15;90(20):e1780-e1788. doi: 10.1212/WNL.0000000000005518. Epub 2018 Apr 13.

16.

Prevalence of preclinical Alzheimer disease: Comparison of current classification systems.

Kern S, Zetterberg H, Kern J, Zettergren A, Waern M, Höglund K, Andreasson U, Wetterberg H, Börjesson-Hanson A, Blennow K, Skoog I.

Neurology. 2018 May 8;90(19):e1682-e1691. doi: 10.1212/WNL.0000000000005476. Epub 2018 Apr 13.

17.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

18.

Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Karikari TK, Charway-Felli A, Höglund K, Blennow K, Zetterberg H.

Front Neurol. 2018 Mar 29;9:201. doi: 10.3389/fneur.2018.00201. eCollection 2018. No abstract available.

19.

Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry.

Kaya I, Zetterberg H, Blennow K, Hanrieder J.

ACS Chem Neurosci. 2018 May 4. doi: 10.1021/acschemneuro.8b00121. [Epub ahead of print]

PMID:
29648443
20.

Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants.

Chatterjee P, Goozee K, Sohrabi HR, Shen K, Shah T, Asih PR, Dave P, ManYan C, Taddei K, Chung R, Zetterberg H, Blennow K, Martins RN.

J Alzheimers Dis. 2018;63(2):479-487. doi: 10.3233/JAD-180025.

PMID:
29630554
21.

Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study.

Axelsson M, Sjögren M, Andersen O, Blennow K, Zetterberg H, Lycke J.

Acta Neurol Scand. 2018 Apr 6. doi: 10.1111/ane.12927. [Epub ahead of print]

PMID:
29624650
22.

Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly.

Skoog I, Kern S, Zetterberg H, Östling S, Börjesson-Hanson A, Guo X, Blennow K.

J Alzheimers Dis. 2018;62(4):1877-1886. doi: 10.3233/JAD-170950.

23.

Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.

Teunissen CE, Chiu MJ, Yang CC, Yang SY, Scheltens P, Zetterberg H, Blennow K.

J Alzheimers Dis. 2018;62(4):1857-1863. doi: 10.3233/JAD-170784.

PMID:
29614646
24.

Longitudinal performance of plasma neurofilament light and tau in professional fighters: The Professional Fighters Brain Health Study.

Bernick C, Zetterberg H, Shan G, Banks S, Blennow K.

J Neurotrauma. 2018 Apr 2. doi: 10.1089/neu.2017.5553. [Epub ahead of print]

PMID:
29609512
25.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Mar 28. pii: S1552-5260(18)30063-3. doi: 10.1016/j.jalz.2018.02.009. [Epub ahead of print]

PMID:
29601787
26.

The Past and the Future of Alzheimer's Disease Fluid Biomarkers.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2018;62(3):1125-1140. doi: 10.3233/JAD-170773.

27.

Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.

Paterson RW, Slattery CF, Poole T, Nicholas JM, Magdalinou NK, Toombs J, Chapman MD, Lunn MP, Heslegrave AJ, Foiani MS, Weston PSJ, Keshavan A, Rohrer JD, Rossor MN, Warren JD, Mummery CJ, Blennow K, Fox NC, Zetterberg H, Schott JM.

Alzheimers Res Ther. 2018 Mar 20;10(1):32. doi: 10.1186/s13195-018-0361-3.

28.

Apolipoprotein E genotypes and longevity across dementia disorders.

Skillbäck T, Lautner R, Mattsson N, Schott JM, Skoog I, Nägga K, Kilander L, Wimo A, Winblad B, Eriksdotter M, Blennow K, Zetterberg H.

Alzheimers Dement. 2018 Mar 13. pii: S1552-5260(18)30045-1. doi: 10.1016/j.jalz.2018.02.003. [Epub ahead of print]

PMID:
29548722
29.

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.

Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P, Lleó A, Perret-Liaudet A, Tumani H, Turner MR, Verbeek MM, Wiltfang J, Zetterberg H, Parnetti L, Blennow K.

Alzheimers Res Ther. 2018 Mar 15;10(1):30. doi: 10.1186/s13195-018-0359-x. Review.

30.

Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease.

Law LL, Rol RN, Schultz SA, Dougherty RJ, Edwards DF, Koscik RL, Gallagher CL, Carlsson CM, Bendlin BB, Zetterberg H, Blennow K, Asthana S, Sager MA, Hermann BP, Johnson SC, Cook DB, Okonkwo OC.

Alzheimers Dement (Amst). 2018 Feb 6;10:188-195. doi: 10.1016/j.dadm.2018.01.001. eCollection 2018.

31.

Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.

Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, Zetterberg H, Heslegrave A, Wild EJ.

Sci Rep. 2018 Mar 9;8(1):4260. doi: 10.1038/s41598-018-21788-x.

32.

Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid.

Clark LR, Berman SE, Norton D, Koscik RL, Jonaitis E, Blennow K, Bendlin BB, Asthana S, Johnson SC, Zetterberg H, Carlsson CM.

Neurology. 2018 Apr 10;90(15):e1306-e1315. doi: 10.1212/WNL.0000000000005291. Epub 2018 Mar 9.

PMID:
29523644
33.

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study.

Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, Vanmechelen E, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE.

Clin Chem. 2018 Jun;64(6):927-937. doi: 10.1373/clinchem.2017.283028. Epub 2018 Mar 9.

PMID:
29523639
34.

Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides.

Cam M, Durieu E, Bodin M, Manousopoulou A, Koslowski S, Vasylieva N, Barnych B, Hammock BD, Bohl B, Koch P, Omori C, Yamamoto K, Hata S, Suzuki T, Karg F, Gizzi P, Haber VE, Bencetic Mihaljevic V, Tavcar B, Portelius E, Pannee J, Blennow K, Zetterberg H, Garbis SD, Auvray P, Gerber H, Fraering J, Fraering PC, Meijer L.

J Alzheimers Dis. 2018;62(4):1663-1681. doi: 10.3233/JAD-170875.

PMID:
29504531
35.

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM; Swedish BioFINDER study group; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Mar 1. pii: S1552-5260(18)30029-3. doi: 10.1016/j.jalz.2018.01.010. [Epub ahead of print]

36.

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.

Niemelä V, Burman J, Blennow K, Zetterberg H, Larsson A, Sundblom J.

PLoS One. 2018 Feb 23;13(2):e0193492. doi: 10.1371/journal.pone.0193492. eCollection 2018.

37.

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease.

Wellington H, Paterson RW, Suárez-González A, Poole T, Frost C, Sjöbom U, Slattery CF, Magdalinou NK, Lehmann M, Portelius E, Fox NC, Blennow K, Zetterberg H, Schott JM.

Ann Clin Transl Neurol. 2018 Jan 11;5(2):162-171. doi: 10.1002/acn3.518. eCollection 2018 Feb.

38.

Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery: Results From the CAPACITY and ARCADIAN Studies.

Evered L, Silbert B, Scott DA, Zetterberg H, Blennow K.

JAMA Neurol. 2018 May 1;75(5):542-547. doi: 10.1001/jamaneurol.2017.4913.

PMID:
29459944
39.

Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.

Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, Zetterberg H, Blennow K, Carlsson CM, Neuhaus J, Bendlin BB, Kramer JH.

J Alzheimers Dis. 2018;62(1):385-397. doi: 10.3233/JAD-170602.

40.

Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.

Malpas CB, Saling MM, Velakoulis D, Desmond P, Hicks RJ, Zetterberg H, Blennow K, O'Brien TJ.

J Alzheimers Dis. 2018;62(1):417-427. doi: 10.3233/JAD-170250.

PMID:
29439322
41.

Neurogranin as a predictor of memory and executive function decline in MCI patients.

Headley A, De Leon-Benedetti A, Dong C, Levin B, Loewenstein D, Camargo C, Rundek T, Zetterberg H, Blennow K, Wright CB, Sun X; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 Mar 6;90(10):e887-e895. doi: 10.1212/WNL.0000000000005057. Epub 2018 Feb 2.

PMID:
29429972
42.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

PMID:
29429971
43.

Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease.

Olsson M, Ärlig J, Hedner J, Blennow K, Zetterberg H.

Sleep. 2018 May 1;41(5). doi: 10.1093/sleep/zsy025.

PMID:
29425372
44.

Genetic variation in FOXO3 is associated with self-rated health in a population-based sample of older individuals.

Zettergren A, Kern S, Rydén L, Östling S, Blennow K, Zetterberg H, Falk H, Skoog I.

J Gerontol A Biol Sci Med Sci. 2018 Feb 5. doi: 10.1093/gerona/gly021. [Epub ahead of print]

PMID:
29415201
45.

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease.

de Leon MJ, Pirraglia E, Osorio RS, Glodzik L, Saint-Louis L, Kim HJ, Fortea J, Fossati S, Laska E, Siegel C, Butler T, Li Y, Rusinek H, Zetterberg H, Blennow K; Alzheimer’s Disease Neuroimaging Initiative; National Alzheimer’s Coordinating Center.

PLoS One. 2018 Feb 7;13(2):e0191240. doi: 10.1371/journal.pone.0191240. eCollection 2018.

46.

Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.

Førland MG, Öhrfelt A, Dalen I, Tysnes OB, Blennow K, Zetterberg H, Pedersen KF, Alves G, Lange J.

Parkinsonism Relat Disord. 2018 Apr;49:4-8. doi: 10.1016/j.parkreldis.2018.01.018. Epub 2018 Jan 31.

PMID:
29409704
47.

Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link.

Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, de Leon MJ, Fossati S.

EBioMedicine. 2018 Feb;28:21-30. doi: 10.1016/j.ebiom.2018.01.021. Epub 2018 Jan 31. Review.

48.

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.

Zerr I, Schmitz M, Karch A, Villar-Piqué A, Kanata E, Golanska E, Díaz-Lucena D, Karsanidou A, Hermann P, Knipper T, Goebel S, Varges D, Sklaviadis T, Sikorska B, Liberski PP, Santana I, Ferrer I, Zetterberg H, Blennow K, Calero O, Calero M, Ladogana A, Sánchez-Valle R, Baldeiras I, Llorens F.

Alzheimers Dement. 2018 Jun;14(6):751-763. doi: 10.1016/j.jalz.2017.12.008. Epub 2018 Feb 3.

PMID:
29391125
49.

A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.

Gaetani L, Höglund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, Sarchielli P, Calabresi P, Di Filippo M, Zetterberg H, Blennow K.

Alzheimers Res Ther. 2018 Jan 23;10(1):8. doi: 10.1186/s13195-018-0339-1.

50.

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.

Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, Zetterberg H, Blennow K.

Alzheimers Res Ther. 2018 Jan 15;10(1):5. doi: 10.1186/s13195-017-0335-x.

Supplemental Content

Loading ...
Support Center